Market Place
Sourcing Support
All News #Library
Biotech
Gyre Therapeutics Receives China NMPA Priority Review
17 Mar 2026 //
GLOBENEWSWIRE
Cullgen Ditches Reverse Merger With Pulmatrix To Go With Gyre
02 Mar 2026 //
FIERCE BIOTECH
Gyre Aligns with China`s CDE on Hydronidone Review
05 Jan 2026 //
GLOBENEWSWIRE
Gyre Therapeutics` Hydronidone Meets Primary Endpoint in Phase 3
22 May 2025 //
GLOBENEWSWIRE
Gyre Therapeutics Plans Public Offering of Common Stock
22 May 2025 //
GLOBENEWSWIRE
Gyre Therapeutics Prices $20.0M Public Offering of Common Stock
22 May 2025 //
GLOBENEWSWIRE
Gyre Therapeutics`s Appointment of Ping to Board of Directors
06 Jan 2025 //
GLOBENEWSWIRE
Gyre Therapeutics Reports Q3 2024 Results & Business Update
13 Nov 2024 //
GLOBENEWSWIRE
Gyre Therapeutics Completes Pivotal Phase 3 Trial For CHB
22 Oct 2024 //
GLOBENEWSWIRE
Gyre Therapeutics to Present at H.C. Wainwright MASH Conference
01 Oct 2024 //
GLOBENEWSWIRE
Gyre Therapeutics To Present At H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
Gyre Therapeutics Reports Q2 2024 Results And Business Update
13 Aug 2024 //
GLOBENEWSWIRE
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
09 Aug 2024 //
GLOBENEWSWIRE
Gyre Therapeutics Appoints David Epstein To Board Of Directors
08 Aug 2024 //
GLOBENEWSWIRE
Gyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In Time
13 Apr 2024 //
SEEKINGALPHA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.